Literature DB >> 7864025

Fibrinogen/fibrin degradation products and D-dimer in clinical practice: interpretation of discrepant results.

N Sato1, H Takahashi, A Shibata.   

Abstract

In clinical practice, occasionally some patients show dissociated values of fibrinogen/fibrin degradation products (FDP) and D-dimer (cross-linked fibrin degradation products). In an attempt to assess the frequency, clinical backgrounds, and hemostatic states of these cases, FDP and D-dimer were simultaneously measured together with other hemostatic parameters in 371 samples from patients with various diseases. As a whole, FDP were elevated in parallel with the progress of activation of blood coagulation and fibrinolysis. However, in patients with elevated FDP and/or D-dimer, 11.5% of samples showed relatively lower D-dimer values than those expected from FDP levels, and these were regarded as an apparently dissociated group. In the dissociated group, activation of coagulation and fibrinolysis occurred to a lesser extent than others. Analysis of these samples suggested that the possible reasons for the dissociation between FDP and D-dimer values were accelerated fibrinogenolysis with or without secondary fibrinolysis, accelerated fibrinogenolysis by non-plasmic proteinases, elevated soluble fibrin, and possibly false-positive FDP levels due to unclottable fibrinogen remaining in the serum samples. In practice, simultaneous measurements of FDP and D-dimer are useful for more accurate estimation of hyperfibrinolytic states.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7864025     DOI: 10.1002/ajh.2830480306

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  8 in total

1.  Tranexamic acid attenuates early post-operative systemic inflammatory response and nutritional loss and avoids reduction of fibrinogen in total hip arthroplasty within an enhanced recovery after surgery pathway.

Authors:  Chen Changjun; Zhao Xin; Luo Yue; Zhao Chengcheng; Wang Qiuru; Li Qianhao; Kang Pengde
Journal:  Int Orthop       Date:  2021-08-18       Impact factor: 3.075

2.  Alveolar fibrinolytic capacity suppressed by injurious mechanical ventilation.

Authors:  Peter Dahlem; Albert P Bos; Jack J Haitsma; Marcus J Schultz; Joost C M Meijers; Burkhard Lachmann
Journal:  Intensive Care Med       Date:  2005-03-08       Impact factor: 17.440

3.  Persistently elevated laboratory markers of thrombosis and fibrinolysis after clinical recovery in malaria points to residual and smouldering cellular damage.

Authors:  Anirban Dasgupta; Sandeep Rai; Amar Das Gupta
Journal:  Indian J Hematol Blood Transfus       Date:  2011-09-10       Impact factor: 0.900

4.  Hemostatic findings of pleural fluid in dogs and the association between pleural effusions and primary hyperfibrino(geno)lysis: A cohort study of 99 dogs.

Authors:  Andrea Zoia; Michele Drigo; Christine J Piek; Paolo Simioni; Marco Caldin
Journal:  PLoS One       Date:  2018-02-20       Impact factor: 3.240

5.  Enhanced fibrinolysis detection in a natural occurring canine model with intracavitary effusions: Comparison and degree of agreement between thromboelastometry and FDPs, D-dimer and fibrinogen concentrations.

Authors:  Andrea Zoia; Michele Drigo; Christine J Piek; Helena Calcini; Marco Caldin; Paolo Simioni
Journal:  PLoS One       Date:  2019-11-14       Impact factor: 3.240

6.  Developing a Nomogram-Based Scoring Tool to Estimate the Risk of Pulmonary Embolism.

Authors:  Qiao Zhou; Xing-Yu Xiong; Zong-An Liang
Journal:  Int J Gen Med       Date:  2022-04-05

Review 7.  Fibrinolysis in Dogs with Intracavitary Effusion: A Review.

Authors:  Andrea Zoia; Michele Drigo; Marco Caldin; Paolo Simioni; Christine J Piek
Journal:  Animals (Basel)       Date:  2022-09-20       Impact factor: 3.231

8.  Early coagulation tests predict risk stratification and prognosis of COVID-19.

Authors:  Lili Luo; Min Xu; Mengyi Du; Haiming Kou; Danying Liao; Zhipeng Cheng; Heng Mei; Yu Hu
Journal:  Aging (Albany NY)       Date:  2020-08-29       Impact factor: 5.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.